Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company developing immunotherapies, has announced promising results from its Phase 1b study of azer-cel, an off-the-shelf, allogeneic CAR T ...
A $7.25 billion class action settlement meant to resolve claims that Monsanto’s Roundup products caused cancer in people has received preliminary approval from a Missouri court, lawyers confirmed on ...
Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...
New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...
She thought it was a case of the flu. As the weeks passed, the Pilates instructor's symptoms worsened. Weiss could no longer ...
Obinutuzumab is a potent anti-B cell drug already approved to treat lupus nephritis, chronic lymphocytic leukemia, and follicular lymphoma. Therapies targeting B cells are perhaps the most effective ...
In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.
The Hematologic Malignancies Market is projected to grow from USD 72,200.85 million in 2024 to USD 128,481.41 million by 2032, registering a CAGR of 7.47% during 2024--2032. Growth is underpinned by ...
The Saturday event, hosted by juniors Tasha McMaster and Westie Davidson, will take place at Resin Gallery in Hermosa Beach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results